<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040075</url>
  </required_header>
  <id_info>
    <org_study_id>184 Resistance Study</org_study_id>
    <nct_id>NCT04040075</nct_id>
  </id_info>
  <brief_title>Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy</brief_title>
  <official_title>Open-label Switch Study From a Regimen of Elvitegravir/Tenofovir Alafenamide/Emtricitabine/Cobicistat and Darunavir, to a FDC of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed HIV-l Subjects Known to Have an 184 V/I Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southampton Healthcare, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southampton Healthcare, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label Study to Evaluate Switching from a Regimen of Elvitegravir/Tenofovir&#xD;
      alafenamide/Emtricitabine/Cobicistat and Darunavir, to a Fixed-Dose Combination of&#xD;
      Bictegravir/Tenofovir alafenamide/Emtricitabine in Virologically Suppressed HIV-1 Subjects&#xD;
      who are known to have a I84 V/I Mutation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>subjects under current treatment for HIV with the I84 I/V Mutation Resistance</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184 V/I resistance mutation.</measure>
    <time_frame>In 48 week study</time_frame>
    <description>Pure Virologic Response (PVR) with HIV-1 RNA &lt; 50 copies/mL at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184 V/I resistance mutation.</measure>
    <time_frame>In 48 Week study</time_frame>
    <description>Pure Virologic Response (PVR) with HIV-1 RNA &lt; 50 copies/mL at week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Pure Virologic Response (PVR) with HIV-1 RNA &lt; 50 copies/mL at week 48</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biktarvy Tab</intervention_name>
    <description>Antiretroviral drug</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The ability to understand and sign a written informed consent which must be obtained&#xD;
             prior to initiation of study procedures.&#xD;
&#xD;
          -  Age equal to or greater than 18 years.&#xD;
&#xD;
          -  Currently receiving an ARV regimen of EVG/F/TAF +DRV greater than six month.&#xD;
&#xD;
          -  Documented plasma HIV - 1 RNA less than 50 copies/ml during the treatment with&#xD;
             Elvitegravir/F/TAF for a minimum of 12 months prior to screening, on two separate&#xD;
             determinations, with one determination within 3 months prior to screening.&#xD;
&#xD;
          -  Have a documented 184 V/I resistant mutation.&#xD;
&#xD;
          -  HIV-1 RNA levels &lt; 50 copies per ml at screening.&#xD;
&#xD;
          -  Estimated GFR &gt;than or equal to 30 mls/min.&#xD;
&#xD;
          -  AST and ALT equal to or less than 5 times upper limit of normal.&#xD;
&#xD;
          -  Total bilirubin less than or equal to 1.5 mg/dl or normal direct bilirubin.&#xD;
&#xD;
          -  Adequate hematologic function (absolute neutrophil count equal to or greater than&#xD;
             750/mm to the third, platelets equal to or greater than 50,000/mm to the third,&#xD;
             Hemoglobin equal to or greater than 8.5 g/dl).&#xD;
&#xD;
          -  Persons of child bearing potential must have negative serum pregnancy test at&#xD;
             screening.&#xD;
&#xD;
          -  Male participants and persons of child bearing potential who engage in heterosexual&#xD;
             intercourse must agree to use our protocol specified methods of contraception.&#xD;
&#xD;
          -  Female participants must agree to refrain from egg donation from first dose of FDC of&#xD;
             B/F/TAF and throughout the study.&#xD;
&#xD;
          -  Male participants must agree to refrain from sperm donation from first dose until at&#xD;
             least 30 days after last dose of drug.&#xD;
&#xD;
          -  Life expectancy equal to or greater than one year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No desire to switch from current antiretroviral treatment.&#xD;
&#xD;
          -  Any previous use of B/F/TAF.&#xD;
&#xD;
          -  Any opportunistic illness indicative of stage 3 HIV diagnosed within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Malignancy within 5 years of screening other than cutaneous Kaposi's sarcoma,&#xD;
             completed resected non melanoma skin cancer, basal cell carcinoma, or noninvasive&#xD;
             cutaneous squamous carcinoma, or completed resected carcinoma in situ of the cervix or&#xD;
             anus. A prior malignancy treated with curative therapy and for which there has been no&#xD;
             evidence of disease for at least 5 years prior to screening.&#xD;
&#xD;
          -  Known hypersensitivity to FDC of B/F/TAF tablets their metabolites or formulation.&#xD;
&#xD;
          -  No active treatment of Hepatitis C during the 48 weeks of the study.&#xD;
&#xD;
          -  Females who are pregnant confirmed by serum pregnancy test.&#xD;
&#xD;
          -  Females who are breast feeding.&#xD;
&#xD;
          -  Suspected Biktarvy resistance mutations, except 184 V/I.&#xD;
&#xD;
          -  Patients who need to take Dofetilide, Rifampin, Rifapentine, Rifabutin, phenobarbital,&#xD;
             phenytoin, carbamazepine, oxcarbazepine, and antiretrovirals not part of the study and&#xD;
             St. John's Wart during.&#xD;
&#xD;
          -  Acute Hepatitis in the 30 days prior to screening.&#xD;
&#xD;
          -  Active tuberculosis infection.&#xD;
&#xD;
          -  Current alcohol or substance use judged by the investigator to potentially interfere&#xD;
             with subject study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southampton Healthcare, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

